コンテンツにジャンプ
国立がん研究センター 中央病院

トップページ > 診療科のご案内 > 呼吸器内科 > 呼吸器内科について > 業績 > 2012年

2012年

  1. Yamamoto, H. Nokihara, Y. Yamada, Y. Goto, M. Tanioka, T. Shibata, K. Yamada, H. Asahina, T. Kawata, X. Shi, T. Tamura. A Phase I, dose-finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors. Cancer Sci .103: 504-509, 2012
  1. Sekine, M. Sumi, Y. Ito, H. Horinouchi, H. Nokihara, N. Yamamoto, H. Kunitoh, Y. Ohe, K. Kubota, T. Tamura. Phase I study of concurrent high-dose three-dimensional conformal radiotherapy with chemotherapy using cisplatin and vinorelbine for unresectable stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 82: 953-959, 2012
  1. Seki, N. Yamamoto, Y. Tamura, Y. Goto, T. Shibata, M. Tanioka, H. Asahina, H. Nokihara, Y. Yamada, T. Shimamoto, K. Noguchi, T. Tamura. Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol .69:1099-1105, 2012
  1. Minami-Shimmyo, Y. Ohe, S. Yamamoto, M. Sumi, H. Nokihara, H. Horinouchi, N. Yamamoto, I. Sekine, K. Kubota, T. Tamura. Risk factors for treatment-related death associated with chemotherapy and thoracic radiotherapy for lung cancer. J Thorac Oncol. 7: 177-182, 2012
  1. Makino, N. Yamamoto, H. Sato, R. Ando, Y. Goto, C. Tanai, H. Asahina, H. Nokihara, I. Sekine, H. Kunitoh, Y. Ohe, E. Sugiyama, N. Yokote, T. Tamura, H. Yamamoto. Pharmacokinetic and pharmacodynamic study on amrubicin and amrubicinol in Japanese patients with lung cancer. Cancer Chemother Pharmacol. 69: 861-869, 2012
  1. A. Makihara, Y. Makino, N. Yamamoto, N. Yokote, H. Nokihara, I. Sekine, Y. Ohe, T. Tamura, H. Yamamoto. Gender difference in hematological toxicity among lung cancer patients receiving amrubicin monotherapy. Jpn J Clin Oncol. 42: 187-1191, 2012
  1. Goto, I. Sekine, M. Tanioka, T. Shibata, C. Tanai, H. Asahina, H. Nokihara, N. Yamamoto, H. Kunitoh, Y. Ohe, H. Kikkawa, E. Ohki, T. Tamura. Figitumumab combined with carboplatin and paclitaxel in treatment-naive Japanese patients with advanced non-small cell lung cancer.. Invest New Drugs .30: 1548-1556, 2012
  1. Asahina, Y. Tamura, H. Nokihara, N. Yamamoto, Y. Seki, T. Shibata, Y. Goto, M. Tanioka, Y. Yamada, A. Coates, Y.L. Chiu, X. Li, R. Pradhan, P.J. Ansell, E.M. McKeegan, M.D. McKee, D.M. Carlson, T. Tamura. An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors. Cancer Chemother Pharmacol .69: 1477-1486, 2012
  1. Asahina, I. Sekine, H. Horinouchi, H. Nokihara, N. Yamamoto, K. Kubota, T. Tamura. Retrospective analysis of third-line and fourth-line chemotherapy for advanced non-small-cell lung cancer. Clin Lung Cancer. 13: 39-43, 201.
  1. Horinouchi H, Sekine I, Sumi M, Ito Y, Nokihara H, Yamamoto N, Ohe Y, Tamura T. Brain metastases after definitive concurrent chemoradiotherapy in patients with stage III lung adenocarcinoma: carcinoembryonic antigen as a potential predictive factor. Cancer Sci. 103(4): 756-9, 2012
  1. Nokihara H, Yamamoto N, Yamada Y, Yamada K, Hirata T, Goto Y, Tanioka M Ikeda Y, Tamura T. A phase I study of BMS-690514 in Japanese patients with advanced or metastatic solid tumors. Cancer Chemother Pharmacol.70(4): 559-65, 2012
  1. Kanai M, Hatano E, Kobayashi S, Fujiwara Y, Sakai D, Kodama Y, Ajiki T, Nagano H, Ioka T. Phase I trial of oral S-1 combined with gemcitabine and cisplatin for advanced biliary tract cancer (KHBO1002). Cancer Chemotherapy and Pharmacology. 69(5): 1181-8, 2012
  1. Fujiwara Y, Kiyota N, Chayahara N, Suzuki A, Umeyama Y, Mukohara T, Minami H. Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients. Investigational New Drugs.30(3): 1055-64, 2012
    ,
  2. Kataoka Y, Mukohara T, Tomioka H, Funakoshi Y, Kiyota N, Fujiwara Y, Yashiro M, Hirakawa K, Hirai M, Minami H.Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks. Investigational New Drugs.30(4);1352-60, 2012
    ,
  3. Tomioka H, Mukohara T, Kataoka Y, Ekyalongo RC, Funakoshi Y, Imai Y, Kiyota N, Fujiwara Y, Minami H.Inhibition of the mTOR/S6K signal is necessary to enhance fluorouracil-induced apoptosis in gastric cancer cells with HER2 amplification. International Journal of Oncology.41(2);551-8:2012
  4. Morita S, Oizumi S, Minami H, Kitagawa K, Komatsu Y, Fujiwara Y, Inada M, Yuki S, Kiyota N, Mitsuma A, Sawaki M, Tanii H, Kimura J, Ando Y. Phase I dose-escalating study of panobinostat (LBH589) administered intravenously to Japanese patients with advanced solid tumors. Investigational New Drugs.30(5);1950-7:2012